Consolidated Statements Of Income | |
Molecular diagnostic testing | 165.1M |
Companion diagnostic services | 12.4M |
Total revenue | 177.5M |
Costs and expenses: | |
Cost of molecular diagnostic testing | 34.3M |
Cost of companion diagnostic services | |
Research and development expense | 19.4M |
Selling, general, and administrative expense | 111.9M |
Total costs and expenses | 171.3M |
Operating income | 6.2M |
Other income (expense): | |
Interest income | 300K |
Other | |
Total other income | |
Income from continuing operations before income taxes | 4M |
Income tax provision (benefit) | 5.2M |
Income from continuing operations | |
Discontinued operations (Note 15) | |
Loss from discontinued operations | |
Net income | -1.2M |
Earnings (loss) per basic share | |
Continuing operations | |
Discontinued operations | |
Earnings per basic share | -0.02 |
Earnings (loss) per diluted share | |
Continuing operations | |
Discontinued operations | |
Earnings per diluted share | -0.02 |
Weighted average shares outstanding | |
Basic | 68.8M |
Diluted | 68.8M |